The Establishment of Dendritic Cell-tumor Fusion Vaccines for Hormone Refractory Prostate Cancer Cell

Overview

Journal Korean J Urol

Specialty Urology

Date 2010 Apr 24

PMID 20414428

Citations 4

Authors

Tae-Beom Kim

Ho Ki Park

Joo Hyun Chang

In Ho Choi

Khae Hawn Kim

Sang Jin Yoon

Min Sung Lee

Han Jung

Choung-Soo Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: Dendritic cell (DC)-based tumor vaccine is an attractive modality for the treatment of hormone-refractory prostate cancer (HRPC) because it has some efficacy and few side effects in patients with poor general conditions. The aim of this study was to establish which is the most effective DC vaccine for the treatment of HRPC. We compared DC vaccine sensitized with tumor lysate and a fusion vaccine of DCs and tumor cells.

Materials And Methods: The DU145 cancer cell line was purchased from the American Type Culture Collection. DCs were cultured from peripheral blood monocytes. Peripheral blood monocytes were cultured in RPMI 1640 medium supplemented with interleukin-4 (IL-4), granulocyte-macrophage colony-stimulating factor, and 10% fetal calf serum. Tumor necrosis factor-alpha was added on day 7 to support maturation. Functional activity was measured in three groups: the DC single-culture group, the DC culture group with DC vaccine sensitized with tumor lysates, and the DC culture group prepared with tumor fusion vaccine made from irradiated tumor cells and monocyte-derived DCs by the polyethylene glycol method.

Results: By FACS analysis, the rate of DC-tumor fusion vaccine was 20.3+/-3%. The IL-12 level produced by the DC-tumor fusion vaccine was significantly higher than that of DCs pulsed with tumor lysate (p<0.05). Also, the generation of interferon-gamma by tumor-specific T cells in the DC-tumor fusion vaccine group was superior to that of DCs pulsed with tumor lysate (p<0.05). In addition, the T cells of the tumor lysate-pulsed DCs and tumor fusion vaccine had 1.6 and 2.5 times the functional activity, respectively, of the DC single-culture group in killing tumor cells in the cytotoxicity assay.

Conclusions: The DC-tumor fusion vaccine seems to be more effective than DC single-culture or DC-tumor lysate vaccine in the treatment of HRPC.

Citing Articles

Allogenic γδ T cell and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma.

Wang Y, Zhu J, Yu W, Wang J, Xia K, Liang C J Bone Oncol. 2020; 21:100214.

PMID: 32368439 PMC: 7184232. DOI: 10.1016/j.jbo.2018.100214.

Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?.

Cicchelero L, Denies S, Devriendt B, de Rooster H, Sanders N Oncoimmunology. 2015; 4(12):e1048413.

PMID: 26587315 PMC: 4635695. DOI: 10.1080/2162402X.2015.1048413.

Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.

Koido S, Homma S, Takahara A, Namiki Y, Komita H, Nagasaki E J Biomed Biotechnol. 2011; 2011:910836.

PMID: 21541197 PMC: 3085507. DOI: 10.1155/2011/910836.

Regulation of tumor immunity by tumor/dendritic cell fusions.

Koido S, Homma S, Hara E, Namiki Y, Takahara A, Komita H Clin Dev Immunol. 2010; 2010:516768.

PMID: 21048993 PMC: 2964897. DOI: 10.1155/2010/516768.

References

Scott-Taylor T, Pettengell R, Clarke I, Stuhler G, La Barthe M, Walden P . Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim Biophys Acta. 2000; 1500(3):265-79. DOI: 10.1016/s0925-4439(99)00108-8. View

Lotze M, Shurin M, Davis I, Amoscato A, Storkus W . Dendritic cell based therapy of cancer. Adv Exp Med Biol. 1997; 417:551-69. DOI: 10.1007/978-1-4757-9966-8_91. View

Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D . Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998; 4(5):594-600. DOI: 10.1038/nm0598-594. View

Murphy G, Tjoa B, RAGDE H, Kenny G, Boynton A . Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. 1996; 29(6):371-80. DOI: 10.1002/(SICI)1097-0045(199612)29:6<371::AID-PROS5>3.0.CO;2-B. View

Bendandi M, Gocke C, Kobrin C, Benko F, Sternas L, Pennington R . Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999; 5(10):1171-7. DOI: 10.1038/13928. View

Kundu S, Engleman E, Benike C, Shapero M, Dupuis M, van Schooten W . A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses. 1998; 14(7):551-60. DOI: 10.1089/aid.1998.14.551. View

Hsu F, Benike C, Fagnoni F, Liles T, Czerwinski D, Taidi B . Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996; 2(1):52-8. DOI: 10.1038/nm0196-52. View

Nestle F, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R . Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998; 4(3):328-32. DOI: 10.1038/nm0398-328. View

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View

10.

Gong J, Chen D, Kashiwaba M, Kufe D . Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med. 1997; 3(5):558-61. DOI: 10.1038/nm0597-558. View

11.

Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, Jacquet C, Yoneda K . CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med. 1996; 184(2):695-706. PMC: 2192705. DOI: 10.1084/jem.184.2.695. View

12.

Lundqvist A, Palmborg A, Bidla G, Whelan M, Pandha H, Pisa P . Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses. Med Oncol. 2004; 21(2):155-65. DOI: 10.1385/MO:21:2:155. View

13.

Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F . Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother. 2002; 51(6):299-310. PMC: 11034221. DOI: 10.1007/s00262-002-0284-4. View

14.

Gilboa E . DC-based cancer vaccines. J Clin Invest. 2007; 117(5):1195-203. PMC: 1857263. DOI: 10.1172/JCI31205. View

15.

Reid C, Stackpoole A, Meager A, Tikerpae J . Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol. 1992; 149(8):2681-8. View

16.

Segel L, Jager E, Elias D, Cohen I . A quantitative model of autoimmune disease and T-cell vaccination: does more mean less?. Immunol Today. 1995; 16(2):80-4. DOI: 10.1016/0167-5699(95)80093-X. View